Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Astraea›
Analysis
AddedJul 3, 2026
UpdatedJul 6, 2026
Astraea

Astraea

Astraea is an agentic AI platform that automates clinical-trial biometrics and regulatory submission deliverables for pharma sponsors.

HQ
San Francisco, CA, US
Founded
2026
Accelerator
Y Combinator logoY CombinatorX26
Loading
Overview
Analysis
Compare
Employees
News

Contents

  1. 01Products & Services
  2. 02Market Outlook
  3. 03Competitive Strengths
  1. 01Products & Services
  2. 02Market Outlook
  3. 03Competitive Strengths

Product Overview

Astraea's platform orchestrates specialized AI agents across the biometrics lifecycle. It automates SDTM and ADaM dataset generation, Define-XML metadata, annotated CRFs, statistical programs, tables/listings/figures, and Pinnacle 21 conformance checks in one controlled system.

The platform is deployed inside the sponsor's validated environment so trial data and PHI remain within the customer's security boundary, and every action is logged, versioned, and reviewable for audit readiness.

Market Outlook

Clinical-trial biometrics remains a large manual bottleneck for pharmaceutical and biotech sponsors, with Phase II/III studies requiring months of statistical programming, data management, and QC across fragmented tools. The cost and delay of manual biometrics work directly affect how quickly new drugs reach patients.

Regulatory pressure to produce CDISC-compliant, submission-ready outputs creates durable demand for automation that preserves traceability and audit readiness, positioning standards-native agentic platforms as a structural opportunity in clinical development.

Competitive Advantages

Astraea's core advantage is a standards-native architecture built around CDISC SDTM, ADaM, and Define-XML from the ground up, rather than bolting standards onto a general-purpose system. Human-in-the-loop checkpoints keep biostatisticians and programmers in control of every material decision.

By deploying inside the sponsor's validated environment, the platform keeps sensitive trial data within the customer's security boundary while compressing biometrics-to-reporting cycles, addressing both speed and compliance requirements that generic automation tools cannot meet.